Literature DB >> 21963259

XX ovarian dysgenesis is caused by a PSMC3IP/HOP2 mutation that abolishes coactivation of estrogen-driven transcription.

David Zangen1, Yotam Kaufman, Sharon Zeligson, Shira Perlberg, Hila Fridman, Moein Kanaan, Maha Abdulhadi-Atwan, Abdulsalam Abu Libdeh, Ayal Gussow, Irit Kisslov, Liran Carmel, Paul Renbaum, Ephrat Levy-Lahad.   

Abstract

XX female gonadal dysgenesis (XX-GD) is a rare, genetically heterogeneous disorder characterized by lack of spontaneous pubertal development, primary amenorrhea, uterine hypoplasia, and hypergonadotropic hypogonadism as a result of streak gonads. Most cases are unexplained but thought to be autosomal recessive. We elucidated the genetic basis of XX-GD in a highly consanguineous Palestinian family by using homozygosity mapping and candidate-gene and whole-exome sequencing. Affected females were homozygous for a 3 bp deletion (NM_016556.2, c.600_602del) in the PSMC3IP gene, leading to deletion of a glutamic acid residue (p.Glu201del) in the highly conserved C-terminal acidic domain. Proteasome 26S subunit, ATPase, 3-Interacting Protein (PSMC3IP)/Tat Binding Protein Interacting Protein (TBPIP) is a nuclear, tissue-specific protein with multiple functions. It is critical for meiotic recombination as indicated by the known role of its yeast ortholog, Hop2. Through the C terminus (not present in yeast), PSMC3IP also coactivates ligand-driven transcription mediated by estrogen, androgen, glucocorticoid, progesterone, and thyroid nuclear receptors. In cell lines, the p.Glu201del mutation abolished PSMC3IP activation of estrogen-driven transcription. Impaired estrogenic signaling can lead to ovarian dysgenesis both by affecting the size of the follicular pool created during fetal development and by failing to counteract follicular atresia during puberty. PSMC3IP joins previous genes known to be mutated in XX-GD, the FSH receptor, and BMP15, highlighting the importance of hormonal signaling in ovarian development and maintenance and suggesting a common pathway perturbed in isolated XX-GD. By analogy to other XX-GD genes, PSMC3IP is also a candidate gene for premature ovarian failure, and its role in folliculogenesis should be further investigated.
Copyright © 2011 The American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21963259      PMCID: PMC3188834          DOI: 10.1016/j.ajhg.2011.09.006

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  43 in total

1.  Identification and characterization of a tissue-specific coactivator, GT198, that interacts with the DNA-binding domains of nuclear receptors.

Authors:  Lan Ko; Guemalli R Cardona; Alexandra Henrion-Caude; William W Chin
Journal:  Mol Cell Biol       Date:  2002-01       Impact factor: 4.272

Review 2.  Sex determination and differentiation.

Authors:  David T MacLaughlin; Patricia K Donahoe
Journal:  N Engl J Med       Date:  2004-01-22       Impact factor: 91.245

3.  Upregulation of the BRCA1 gene in human germ cells and in preimplantation embryos.

Authors:  Sandrine Giscard d'Estaing; Delphine Perrin; Gilbert M Lenoir; Jean François Guérin; Robert Dante
Journal:  Fertil Steril       Date:  2005-09       Impact factor: 7.329

4.  Molecular activities of meiosis-specific proteins Hop2, Mnd1, and the Hop2-Mnd1 complex.

Authors:  Roberto J Pezza; Galina V Petukhova; Rodolfo Ghirlando; R Daniel Camerini-Otero
Journal:  J Biol Chem       Date:  2006-05-04       Impact factor: 5.157

5.  Mutations in the DBP-deficiency protein HSD17B4 cause ovarian dysgenesis, hearing loss, and ataxia of Perrault Syndrome.

Authors:  Sarah B Pierce; Tom Walsh; Karen M Chisholm; Ming K Lee; Anne M Thornton; Agata Fiumara; John M Opitz; Ephrat Levy-Lahad; Rachel E Klevit; Mary-Claire King
Journal:  Am J Hum Genet       Date:  2010-07-30       Impact factor: 11.025

6.  Generation of a transcription map at the HSD17B locus centromeric to BRCA1 at 17q21.

Authors:  J M Rommens; F Durocher; J McArthur; P Tonin; J F LeBlanc; T Allen; C Samson; L Ferri; S Narod; K Morgan
Journal:  Genomics       Date:  1995-08-10       Impact factor: 5.736

7.  Men homozygous for an inactivating mutation of the follicle-stimulating hormone (FSH) receptor gene present variable suppression of spermatogenesis and fertility.

Authors:  J S Tapanainen; K Aittomäki; J Min; T Vaskivuo; I T Huhtaniemi
Journal:  Nat Genet       Date:  1997-02       Impact factor: 38.330

8.  Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure.

Authors:  K Aittomäki; J L Lucena; P Pakarinen; P Sistonen; J Tapanainen; J Gromoll; R Kaskikari; E M Sankila; H Lehväslaiho; A R Engel; E Nieschlag; I Huhtaniemi; A de la Chapelle
Journal:  Cell       Date:  1995-09-22       Impact factor: 41.582

9.  Global gene expression in the human fetal testis and ovary.

Authors:  Brenda Houmard; Christopher Small; Lizhong Yang; Theresa Naluai-Cecchini; Edith Cheng; Terry Hassold; Michael Griswold
Journal:  Biol Reprod       Date:  2009-04-15       Impact factor: 4.285

Review 10.  Molecular pathology of the FSH receptor: new insights into FSH physiology.

Authors:  G Meduri; A Bachelot; M P Cocca; C Vasseur; P Rodien; F Kuttenn; P Touraine; M Misrahi
Journal:  Mol Cell Endocrinol       Date:  2007-12-04       Impact factor: 4.102

View more
  41 in total

Review 1.  Dynamics of the ovarian reserve and impact of genetic and epidemiological factors on age of menopause.

Authors:  Emanuele Pelosi; Eleanor Simonsick; Antonino Forabosco; Jose Elias Garcia-Ortiz; David Schlessinger
Journal:  Biol Reprod       Date:  2015-04-22       Impact factor: 4.285

Review 2.  Insights from exome sequencing for endocrine disorders.

Authors:  Christiaan de Bruin; Andrew Dauber
Journal:  Nat Rev Endocrinol       Date:  2015-05-12       Impact factor: 43.330

3.  Mutations in LARS2, encoding mitochondrial leucyl-tRNA synthetase, lead to premature ovarian failure and hearing loss in Perrault syndrome.

Authors:  Sarah B Pierce; Ksenija Gersak; Rachel Michaelson-Cohen; Tom Walsh; Ming K Lee; Daniel Malach; Rachel E Klevit; Mary-Claire King; Ephrat Levy-Lahad
Journal:  Am J Hum Genet       Date:  2013-03-28       Impact factor: 11.025

4.  A mutation in the nucleoporin-107 gene causes XX gonadal dysgenesis.

Authors:  Ariella Weinberg-Shukron; Paul Renbaum; Rachel Kalifa; Sharon Zeligson; Ziva Ben-Neriah; Amatzia Dreifuss; Amal Abu-Rayyan; Noa Maatuk; Nilly Fardian; Dina Rekler; Moien Kanaan; Abraham O Samson; Ephrat Levy-Lahad; Offer Gerlitz; David Zangen
Journal:  J Clin Invest       Date:  2015-10-20       Impact factor: 14.808

5.  Concerns regarding the potentially causal role of FANCA heterozygous variants in human primary ovarian insufficiency.

Authors:  Abdelkader Heddar; Micheline Misrahi
Journal:  Hum Genet       Date:  2020-11-05       Impact factor: 4.132

6.  Functional study of a novel c.630delG (p.Y211Tfs*85) mutation in NR5A1 gene in a Chinese boy with 46,XY disorders of sex development.

Authors:  Sinian Pan; Shili Guo; Liting Liu; Xiaoyuan Yang; Hanmei Liang
Journal:  J Assist Reprod Genet       Date:  2020-01-14       Impact factor: 3.412

Review 7.  Exome sequencing greatly expedites the progressive research of Mendelian diseases.

Authors:  Xuejun Zhang
Journal:  Front Med       Date:  2014-01-03       Impact factor: 4.592

Review 8.  The application of next-generation sequencing in the autozygosity mapping of human recessive diseases.

Authors:  Fowzan S Alkuraya
Journal:  Hum Genet       Date:  2013-08-02       Impact factor: 4.132

9.  Oncoprotein GT198 vaccination delays tumor growth in MMTV-PyMT mice.

Authors:  Bhagelu R Achyut; Hao Zhang; Kartik Angara; Nahid F Mivechi; Ali S Arbab; Lan Ko
Journal:  Cancer Lett       Date:  2020-02-12       Impact factor: 8.679

10.  Human ovarian cancer stroma contains luteinized theca cells harboring tumor suppressor gene GT198 mutations.

Authors:  Min Peng; Hao Zhang; Lahcen Jaafar; John I Risinger; Shuang Huang; Nahid F Mivechi; Lan Ko
Journal:  J Biol Chem       Date:  2013-10-04       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.